U.S. markets open in 4 hours 1 minute
  • S&P Futures

    4,383.50
    +35.25 (+0.81%)
     
  • Dow Futures

    34,147.00
    +308.00 (+0.91%)
     
  • Nasdaq Futures

    15,115.75
    +106.25 (+0.71%)
     
  • Russell 2000 Futures

    2,203.10
    +26.30 (+1.21%)
     
  • Crude Oil

    71.35
    +1.06 (+1.51%)
     
  • Gold

    1,765.20
    +1.40 (+0.08%)
     
  • Silver

    22.50
    +0.29 (+1.31%)
     
  • EUR/USD

    1.1740
    +0.0012 (+0.11%)
     
  • 10-Yr Bond

    1.3090
    0.0000 (0.00%)
     
  • Vix

    22.92
    +2.11 (+10.14%)
     
  • GBP/USD

    1.3685
    +0.0026 (+0.19%)
     
  • USD/JPY

    109.5630
    +0.1430 (+0.13%)
     
  • BTC-USD

    43,250.54
    -1,846.47 (-4.09%)
     
  • CMC Crypto 200

    1,085.91
    -48.47 (-4.27%)
     
  • FTSE 100

    6,971.50
    +67.59 (+0.98%)
     
  • Nikkei 225

    29,839.71
    -660.34 (-2.17%)
     

Lexaria Announces Voluntary Delisting from the Canadian Securities Exchange to Concentrate Trading on the Nasdaq Capital Markets

  • Oops!
    Something went wrong.
    Please try again later.
·4 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

KELOWNA, BC / ACCESSWIRE / July 5, 2021/ Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE: LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms announces that on June 30, 2021 it made a request to voluntarily delist its common shares from the Canadian Securities Exchange (the “CSE”). It is expected that the close of business on Wednesday, July 7, 2021 will be the final trading day for Lexaria on the CSE. At the open of the trading day on July 8, 2021, the Company's shares will only trade on the NASDAQ Capital Markets ('Nasdaq').

Since Lexaria's shares began trading on the Nasdaq in January 2021, the overwhelming majority of trading has moved to Nasdaq, providing more liquidity for shareholders than ever before experienced. The Company expects to realize savings in fees and managerial time and effort that were required to maintain a dual listing that can now be redirected into the Company's applied research and development programs, further advancing the business of the Company. For these reasons, Lexaria's management team and Board of Directors have made the decision to voluntarily delist from the CSE, consolidating the trading of its shares to Nasdaq.

All shareholders can continue trading Lexaria's shares on Nasdaq under the symbol “LEXX”. The Company has confirmed that Nasdaq listed securities are designated as a “qualified investment” for the purposes of maintaining Lexaria shares in Canadian Registered Savings Plans, including RRSP, RESP, RRIF, RDSP and TFSA.

About Lexaria Bioscience Corp.

Lexaria Bioscience Corp.'s proprietary drug delivery technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules, thereby lowering overall dosing. The Company's technology can be applied to many different ingestible product formats, including foods, beverages, oral suspensions, tablets, and capsules. DehydraTECH has repeatedly demonstrated since 2016 with cannabinoids and nicotine the ability to increase bio-absorption by up to 5-10x, reduce time of onset from 1 - 2 hours to minutes, and mask unwanted tastes; and is planned to be further evaluated for orally administered bioactive molecules, including anti-virals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), and nicotine. Lexaria has licensed DehydraTECH to multiple companies including a world-leading tobacco producer for the development of smokeless, oral-based nicotine products and for use in industries that produce cannabinoid beverages, edibles, and oral products. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 19 patents granted and approximately 60 patents pending worldwide. For more information, please visit www.lexariabioscience.com.

CAUTION REGARDING FORWARD-LOOKING STATEMENTS

This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as 'anticipate,' 'if,' 'believe,' 'plan,' 'estimate,' 'expect,' 'intend,' 'may,' 'could,' 'should,' 'will,' and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the company relating the Company's ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company's ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.

INVESTOR CONTACT:

ir@lexariabioscience.com

Phone: 250-765-6424, ext 202

SOURCE: Lexaria Bioscience Corp.



View source version on accesswire.com:
https://www.accesswire.com/654192/Lexaria-Announces-Voluntary-Delisting-from-the-Canadian-Securities-Exchange-to-Concentrate-Trading-on-the-Nasdaq-Capital-Markets